Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Phenylephrine hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Minims® Phenylephrine Hydrochloride contains a mydriatic agent. It is used to enlarge the pupil of your eye. Your doctor or eye specialist may use it to examine your eye more closely or as part of a treatment program. Minims® Phenylephrine Hydrochloride 2.5% is indicated for children, adults and the elderly. Minims® Phenylephrine Hydrochloride 10% is not indicated for children or the elderly, as this concentration is too strong. The doctor or eye specialist will use an alternative medicine in these patients.
e Minims® Phenylephrine Hydrochloride eye drops Do not use Minims® Phenylephrine Hydrochloride drops:
Ask yourself the following questions:
Minims® Phenylephrine Hydrochloride eye drops Sometimes a drop of local anaesthetic may be used prior to Minims® Phenylephrine Hydrochloride to prevent the stinging effect of phenylephrine eye drops. The drops are for single use only and provided in single use Minims units, to treat both eyes if both eyes are affected. Once opened, use immediately. Discard any unused portion. Dosage The recommended dose is one drop in each eye. If necessary this can be repeated once only at least one hour after the first drop. Phenylephrine 2.5% w/v: For examination of the eye, the normal dose for adults, elderly and children, is one drop in each eye. If necessary this can be repeated once only at least one hour after the first drop. Phenylephrine 10% w/v: For adults the same dose is recommended. However, Minims Phenylephrine 10% w/v should not be used in children below the age of 12 years. Phenylephrine 10% w/v is not recommended for use in children aged 12 to 18 years or elderly patients. If you are
receiving this product as part of a treatment programme your doctor may suggest an additional dose schedule of one drop every 24 hours of the 2.5% w/v product. Method of administration Parents must be careful not to get this preparation in their children's mouth or cheeks and to wash their hands and the child's hands or cheeks following administration. The doctor or eye specialist will normally put the drops in your eye for you, but if you are putting the eye drops in yourself, then follow these instructions carefully: 1. Wash your hands. 2. Use a mirror, this will help you to see what you are doing. 3. Carefully dry your eyes using a tissue. Twist and pull cap to separate from the Minims body (Diagram 1). 4. Pull your lower eyelid down gently, and then carefully place 1 drop inside your lower eyelid. 5. Close your eye and blink a few times to make sure your eye is covered by the liquid. 6. Close the eyelids. It is advisable to press gently on the inner corner of your eyelid for 3 minutes. This will help stop the solution draining into your nose and throat. 7. Repeat steps 4, 5 and 6 for the other eye if necessary, then throw away the Minims unit, even if some solution remains.
If you use more Minims® Phenylephrine Hydrochloride than you should, an overdose is very unlikely to occur. If you suddenly feel unwell after receiving the drops, tell your doctor or eye specialist or contact your nearest emergency department immediately. If you forget to use Minims® Phenylephrine Hydrochloride, you should take the missed dose as soon as you remember, unless it is nearly time for the next dose, but you should not take a double dose to make up for a missed dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Minims® Phenylephrine Hydrochloride may sting when the drops are first put in and your vision may become blurred. This will gradually wear off. Serious side effects
your eye drops Keep this medicine out of the sight and reach of children. Do not use the eye drops after the expiry date which is stated on the overwrap of each unit and on the carton after the letters "EXP". The expiry date refers to the last day of that month. Do not store above 25°C. Do not freeze. Store in the original package in order to protect from light. The drops are for single use only and provided in single use Minims units, to treat both eyes if both eyes are affected. Once opened, use immediately. Discard any unused portion. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.
What do your eye drops contain
Minims Phenylephrine Hydrochloride 10%w/v Eye drops, solution comes as eye drops containing 10%. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Minims Phenylephrine Hydrochloride 10%w/v Eye drops, solution is phenylephrine hydrochloride.
This leaflet reproduces the patient information leaflet approved for Minims Phenylephrine Hydrochloride 10%w/v Eye drops, solution, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Phenylephrine is a directly acting sympathomimetic agent used topically in the eye as a mydriatic. It may be indicated to dilate the pupil in diagnostic or therapeutic procedures.
Posology
Adults
Apply one drop to each eye. If necessary, this dose may be repeated once only, at least one hour after the first drop.
Paediatric population
Phenylephrine 10% is contraindicated in children aged below 12 years (see section 4.3).
There is no data in children aged 12 to 18 years. Phenylephrine is not recommended in these patients.
Elderly population
The use of phenylephrine 10% solution is contraindicated in this group because of the increased risks of systemic toxicity(see section 4.3).
Method of administration
The use of a drop of topical anaesthetic a few minutes before instillation of phenylephrine is recommended to prevent stinging.
Patients with cardiac disease, hypertension, aneurysms, thyrotoxicosis, long-standing insulin dependent diabetes mellitus and tachycardia.
Children aged below 12 years (see section 4.4).
The elderly, because of the increased risk of systemic toxicity.
Patients on monoamine oxidase inhibitors, tricyclic anti-depressants and antihypertensive agents (including beta-blockers).
Patients with closed angle glaucoma (unless previously treated with iridectomy) and patients with a narrow angle prone to glaucoma precipitated by mydriatics.
Hypersensitivity to phenylephrine or to any of the excipients listed in section 6.1.
Use with caution in the presence of diabetes, cerebral arteriosclerosis or long standing bronchial asthma.
To reduce the risk of precipitating an attack of narrow angle glaucoma evaluate the anterior chamber angle before use.
Ocular hyperaemia can increase the absorption of phenylephrine given topically.
Corneal clouding may occur if phenylephrine 10% is instilled when the corneal epithelium has been denuded or damaged.
Systemic absorption may be minimised by compressing the lacrimal sac at the medial canthus for one minute during and after the instillation of the drops. This blocks the passage of the drops via the naso-lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa.
Paediatric population
Use in children aged below 12 years is contraindicated, since serious systemic adverse reactions have been reported with ophthalmic products containing phenylephrine.
Use in children aged 12 to 18 years is not recommended as adequate clinical experience is missing.
Anti-hypertensive Agents
Topical phenylephrine should not be used as it may reverse the action of many antihypertensive agents with possibly fatal consequences.
Monoamine Oxidase Inhibitors
There is an increased risk of adrenergic reactions when used simultaneously with, or up to three weeks after, the administration of MAOIs.
Tricyclic Anti-depressants
The pressor response to adrenergic agents and the risk of cardiac arrhythmia may be potentiated in patients receiving tricyclic anti-depressants (or within several days of their discontinuation).
Halothane
Because of the increased risk of ventricular fibrillation, phenylephrine should be used with caution during general anaesthesia with anaesthetic agents which sensitise the myocardium to sympathomimetics.
Cardiac Glycosides or Quinidine
There is an increased risk of arrhythmias.
Safety for use in pregnancy and lactation has not been established. This product should only be used during pregnancy if it is considered by the physician to be essential.
May cause stinging and temporarily blurred vision. Warn patients not to drive or operate hazardous machinery until vision is clear.
The frequency of the undesirable effects are not known (cannot be estimated from the available data).
Immune System Disorders
Hypersensitivity
Eye Disorders
Eye pain, eye irritation, vision blurred, photophobia, allergic conjunctivitis.
Cardiac disorders
Palpitations, tachycardia, extrasystoles, arrhythmias.
Arteriospasm coronary, ventricular arrhythmia and myocardial infarction. These sometimes fatal reactions have usually occurred in patients with pre-existing cardiovascular disease.
Vascular disorders
Hypertension
Paediatric population
Respiratory, thoracic and mediastinal disorders
Pulmonary oedema
Reporting of suspected adverse reactions:
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme:
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Because a severe toxic reaction to phenylephrine is of rapid onset and short duration, treatment is primarily supportive. Prompt injection of a rapidly acting alpha adrenergic blocking agent such as phentolamine (dose 2 to 5mg iv) has been recommended.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Medicines sold in Poland with the same active substance: W Polsce znany jako
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Polish medicines in the UK →
Ask anything about Minims Phenylephrine Hydrochloride 10%w/v Eye drops, solution. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.